Tweet
Introduction to VirCapSeq-VERT
The Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health has been at the forefront of developing innovative diagnostic technologies. In 2015, they introduced VirCapSeq-VERT, an advanced next-generation sequencing (NGS)-based system, enhancing the capabilities of pathogen detection. This system represents a significant advancement in the field of clinical diagnostics, particularly in the detection of viruses.
The Technology Behind VirCapSeq-VERT
Traditional diagnostic tools, such as PCR and antigen tests, are designed to identify specific, known pathogens. These targeted assays have been indispensable, especially evident during the COVID-19 pandemic. However, their reactive nature means they are typically available only after an outbreak has begun. In contrast, VirCapSeq-VERT offers a broad-range detection capability, encompassing both known and unknown viruses, with improved sensitivity and speed compared to other NGS platforms.
Validation and Regulatory Approval
The effectiveness of the latest edition of VirCapSeq-VERT was recently validated in a study published in the Journal of Clinical Microbiology. This validation was part of the regulatory application process in New York State, which approved VirCapSeq for the detection of nucleic acids of both DNA and RNA viruses in plasma and nasal swabs. The study involved thorough assessments of VirCapSeq's limit of detection, consistency, ability to identify mixed infections, and accuracy in clinical scenarios. Impressively, VirCapSeq-VERT achieved a clinical sensitivity of 99 percent and 100 percent clinical specificity.
Broad Applications and Future Prospects
Since its inception, VirCapSeq has been utilized globally in studies to investigate various outbreaks and for surveillance in humans, domestic animals, and wildlife. The technology has been accelerated through a partnership with the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. This collaboration aims to bolster U.S. preparedness for future outbreaks and enhance infectious disease diagnostics.
Expert Opinions
Vishal Kapoor, MS, Deputy Director for Laboratory Medicine at the CII, emphasized the uniqueness of VirCapSeq. “VirCapSeq is the only sequencing technology with regulatory approvals that has the broad range coverage of unbiased high throughput sequencing with significantly greater sensitivity in the detection and identification of all vertebrate viruses, including new and emerging species,” he stated. Kapoor further highlighted the potential of VirCapSeq in early identification of viral threats, which could be crucial in containing outbreaks and preventing pandemics.
Echoing this sentiment, W. Ian Lipkin, MD, John Snow Professor of Epidemiology and CII Director, pointed out the transformative potential of VirCapSeq in precision medicine. “Our technology is poised to transform precision medicine, giving caregivers the ability to quickly pinpoint the cause of an infection so as to guide treatment,” Lipkin said. He also emphasized the public health benefits of the technology, providing vital information on circulating viruses in communities.
The Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health has been at the forefront of developing innovative diagnostic technologies. In 2015, they introduced VirCapSeq-VERT, an advanced next-generation sequencing (NGS)-based system, enhancing the capabilities of pathogen detection. This system represents a significant advancement in the field of clinical diagnostics, particularly in the detection of viruses.
The Technology Behind VirCapSeq-VERT
Traditional diagnostic tools, such as PCR and antigen tests, are designed to identify specific, known pathogens. These targeted assays have been indispensable, especially evident during the COVID-19 pandemic. However, their reactive nature means they are typically available only after an outbreak has begun. In contrast, VirCapSeq-VERT offers a broad-range detection capability, encompassing both known and unknown viruses, with improved sensitivity and speed compared to other NGS platforms.
Validation and Regulatory Approval
The effectiveness of the latest edition of VirCapSeq-VERT was recently validated in a study published in the Journal of Clinical Microbiology. This validation was part of the regulatory application process in New York State, which approved VirCapSeq for the detection of nucleic acids of both DNA and RNA viruses in plasma and nasal swabs. The study involved thorough assessments of VirCapSeq's limit of detection, consistency, ability to identify mixed infections, and accuracy in clinical scenarios. Impressively, VirCapSeq-VERT achieved a clinical sensitivity of 99 percent and 100 percent clinical specificity.
Broad Applications and Future Prospects
Since its inception, VirCapSeq has been utilized globally in studies to investigate various outbreaks and for surveillance in humans, domestic animals, and wildlife. The technology has been accelerated through a partnership with the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. This collaboration aims to bolster U.S. preparedness for future outbreaks and enhance infectious disease diagnostics.
Expert Opinions
Vishal Kapoor, MS, Deputy Director for Laboratory Medicine at the CII, emphasized the uniqueness of VirCapSeq. “VirCapSeq is the only sequencing technology with regulatory approvals that has the broad range coverage of unbiased high throughput sequencing with significantly greater sensitivity in the detection and identification of all vertebrate viruses, including new and emerging species,” he stated. Kapoor further highlighted the potential of VirCapSeq in early identification of viral threats, which could be crucial in containing outbreaks and preventing pandemics.
Echoing this sentiment, W. Ian Lipkin, MD, John Snow Professor of Epidemiology and CII Director, pointed out the transformative potential of VirCapSeq in precision medicine. “Our technology is poised to transform precision medicine, giving caregivers the ability to quickly pinpoint the cause of an infection so as to guide treatment,” Lipkin said. He also emphasized the public health benefits of the technology, providing vital information on circulating viruses in communities.